{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:30:39Z","timestamp":1791995439186,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T00:00:00Z","timestamp":1508284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T00:00:00Z","timestamp":1508284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pompe disease is caused by an inborn defect of lysosomal acid \u03b1-glucosidase (GAA) and is characterized by lysosomal glycogen accumulation primarily in the skeletal muscle and heart. Patients with the severe type of the disease, infantile-onset Pompe disease (IOPD), show generalized muscle weakness and heart failure in early infancy. They cannot survive over two years. Enzyme replacement therapy with recombinant human GAA (rhGAA) improves the survival rate, but its effect on skeletal muscle is insufficient compared to other organs. Moreover, the patho-mechanism of skeletal muscle damage in IOPD is still unclear. Here we generated induced pluripotent stem cells (iPSCs) from patients with IOPD and differentiated them into myocytes. Differentiated myocytes showed lysosomal glycogen accumulation, which was dose-dependently rescued by rhGAA. We further demonstrated that mammalian\/mechanistic target of rapamycin complex 1 (mTORC1) activity was impaired in IOPD iPSC-derived myocytes. Comprehensive metabolomic and transcriptomic analyses suggested the disturbance of mTORC1-related signaling, including deteriorated energy status and suppressed mitochondrial oxidative function. In summary, we successfully established an <jats:italic>in vitro<\/jats:italic> skeletal muscle model of IOPD using patient-specific iPSCs. Disturbed mTORC1 signaling may contribute to the pathogenesis of skeletal muscle damage in IOPD, and may be a potential therapeutic target for Pompe disease.<\/jats:p>","DOI":"10.1038\/s41598-017-14063-y","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T11:41:19Z","timestamp":1507808479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["A Skeletal Muscle Model of Infantile-onset Pompe Disease with Patient-specific iPS Cells"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-064X","authenticated-orcid":false,"given":"Takeshi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9004-3172","authenticated-orcid":false,"given":"Tomonari","family":"Awaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Jonouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Era","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Heike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,18]]},"reference":[{"key":"14063_CR1","doi-asserted-by":"publisher","unstructured":"Kishnani, P. S. & Howell, R. R. Pompe disease in infants and children. J. Pediatr. 144, S35\u201343, https:\/\/doi.org\/10.1016\/j.jpeds.2004.01.053 (2004).","DOI":"10.1016\/j.jpeds.2004.01.053"},{"key":"14063_CR2","doi-asserted-by":"crossref","unstructured":"Kishnani, P. S. et al. Pompe disease diagnosis and management guideline. Genet. Med. 8, 267\u2013288, 10.109701.gim.0000218152.87434.f3 (2006).","DOI":"10.1097\/01.gim.0000218152.87434.f3"},{"key":"14063_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HM van den Hout","year":"2003","unstructured":"van den Hout, H. M. et al. The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics \n                           112, 332\u2013340 (2003).","journal-title":"Pediatrics"},{"key":"14063_CR4","doi-asserted-by":"publisher","unstructured":"Kishnani, P. S. et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. 148, 671\u2013676, https:\/\/doi.org\/10.1016\/j.jpeds.2005.11.033 (2006).","DOI":"10.1016\/j.jpeds.2005.11.033"},{"key":"14063_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","volume":"252","author":"LP Winkel","year":"2005","unstructured":"Winkel, L. P. et al. The natural course of non-classic Pompe\u2019s disease; a review of 225 published cases. J. Neurol. \n                           252, 875\u2013884, https:\/\/doi.org\/10.1007\/s00415-005-0922-9 (2005).","journal-title":"J. Neurol."},{"key":"14063_CR6","doi-asserted-by":"crossref","unstructured":"Amalfitano, A. et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet. Med. 3, 132\u2013138, 10.109700125817-200103000-00007 (2001).","DOI":"10.1097\/00125817-200103000-00008"},{"key":"14063_CR7","doi-asserted-by":"publisher","unstructured":"Kishnani, P. S. et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology \n                           68, 99\u2013109, https:\/\/doi.org\/10.1212\/01.wnl.0000251268.41188.04 (2007).","DOI":"10.1212\/01.wnl.0000251268.41188.04"},{"key":"14063_CR8","doi-asserted-by":"publisher","unstructured":"Kishnani, P. S. et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. 99, 26\u201333, https:\/\/doi.org\/10.1016\/j.ymgme.2009.08.003 (2010).","DOI":"10.1016\/j.ymgme.2009.08.003"},{"key":"14063_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria, S. G. et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet. Med. \n                           13, 729\u2013736, https:\/\/doi.org\/10.1097\/GIM.0b013e3182174703 (2011).","journal-title":"Genet. Med."},{"key":"14063_CR10","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/labinvest.3700484","volume":"86","author":"BL Thurberg","year":"2006","unstructured":"Thurberg, B. L. et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab. Invest. \n                           86, 1208\u20131220, https:\/\/doi.org\/10.1038\/labinvest.3700484 (2006).","journal-title":"Lab. Invest."},{"key":"14063_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02889849","volume":"45","author":"JL Griffin","year":"1984","unstructured":"Griffin, J. L. Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol. \n                           45, 23\u201336 (1984).","journal-title":"Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol."},{"key":"14063_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4161\/auto.4591","volume":"3","author":"N Raben","year":"2007","unstructured":"Raben, N. et al. Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand. Autophagy \n                           3, 546\u2013552 (2007).","journal-title":"Autophagy"},{"key":"14063_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ana.20807","volume":"59","author":"T Fukuda","year":"2006","unstructured":"Fukuda, T. et al. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann. Neurol. \n                           59, 700\u2013708, https:\/\/doi.org\/10.1002\/ana.20807 (2006).","journal-title":"Ann. Neurol."},{"key":"14063_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4161\/auto.2984","volume":"2","author":"T Fukuda","year":"2006","unstructured":"Fukuda, T. et al. Autophagy and lysosomes in Pompe disease. Autophagy \n                           2, 318\u2013320 (2006).","journal-title":"Autophagy"},{"key":"14063_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","volume":"14","author":"T Fukuda","year":"2006","unstructured":"Fukuda, T. et al. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol. Ther. \n                           14, 831\u2013839, https:\/\/doi.org\/10.1016\/j.ymthe.2006.08.009 (2006).","journal-title":"Mol. Ther."},{"key":"14063_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ymgme.2010.08.001","volume":"101","author":"N Raben","year":"2010","unstructured":"Raben, N. et al. Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol. Genet. Metab. \n                           101, 324\u2013331, https:\/\/doi.org\/10.1016\/j.ymgme.2010.08.001 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"14063_CR17","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2504","volume":"17","author":"G Tiscornia","year":"2011","unstructured":"Tiscornia, G., Vivas, E. L. & Izpisua Belmonte, J. C. Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. Nat. Med. \n                           17, 1570\u20131576, https:\/\/doi.org\/10.1038\/nm.2504 (2011).","journal-title":"Nat. Med."},{"key":"14063_CR18","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1093\/hmg\/ddr424","volume":"20","author":"HP Huang","year":"2011","unstructured":"Huang, H. P. et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum. Mol. Genet. \n                           20, 4851\u20134864, https:\/\/doi.org\/10.1093\/hmg\/ddr424 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"14063_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.23","volume":"2","author":"Y Sato","year":"2015","unstructured":"Sato, Y. et al. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient. Mol Ther Methods Clin Dev \n                           2, 15023, https:\/\/doi.org\/10.1038\/mtm.2015.23 (2015).","journal-title":"Mol Ther Methods Clin Dev"},{"key":"14063_CR20","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1074\/jbc.M114.628628","volume":"290","author":"KK Raval","year":"2015","unstructured":"Raval, K. K. et al. Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes. J. Biol. Chem. \n                           290, 3121\u20133136, https:\/\/doi.org\/10.1074\/jbc.M114.628628 (2015).","journal-title":"J. Biol. Chem."},{"key":"14063_CR21","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2015-0409","author":"Y Sato","year":"2016","unstructured":"Sato, Y. et al. Metabolomic Profiling of Pompe Disease-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals That Oxidative Stress Is Associated With Cardiac and Skeletal Muscle Pathology. Stem Cells Transl Med. https:\/\/doi.org\/10.5966\/sctm.2015-0409 (2016).","journal-title":"Stem Cells Transl Med"},{"key":"14063_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.54","volume":"3","author":"Y Sato","year":"2016","unstructured":"Sato, Y. et al. TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle. Mol Ther Methods Clin Dev \n                           3, 16054, https:\/\/doi.org\/10.1038\/mtm.2016.54 (2016).","journal-title":"Mol Ther Methods Clin Dev"},{"key":"14063_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell \n                           131, 861\u2013872, https:\/\/doi.org\/10.1016\/j.cell.2007.11.019 (2007).","journal-title":"Cell"},{"key":"14063_CR24","doi-asserted-by":"publisher","first-page":"14152","DOI":"10.1073\/pnas.1009374107","volume":"107","author":"M Nakagawa","year":"2010","unstructured":"Nakagawa, M., Takizawa, N., Narita, M., Ichisaka, T. & Yamanaka, S. Promotion of direct reprogramming by transformation-deficient Myc. Proc. Natl. Acad. Sci. USA \n                           107, 14152\u201314157, https:\/\/doi.org\/10.1073\/pnas.1009374107 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"14063_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/stem.1293","volume":"31","author":"K Okita","year":"2013","unstructured":"Okita, K. et al. An Efficient Nonviral Method to Generate Integration-Free Human-Induced Pluripotent Stem Cells from Cord Blood and Peripheral Blood Cells. Stem Cells \n                           31, 458\u2013466, https:\/\/doi.org\/10.1002\/stem.1293 (2013).","journal-title":"Stem Cells"},{"key":"14063_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061540","volume":"8","author":"A Tanaka","year":"2013","unstructured":"Tanaka, A. et al. Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro. PLoS One \n                           8, e61540, https:\/\/doi.org\/10.1371\/journal.pone.0061540 (2013).","journal-title":"PLoS One"},{"key":"14063_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/0020-711X(89)90138-9","volume":"21","author":"PC Calder","year":"1989","unstructured":"Calder, P. C. & Geddes, R. Rat skeletal muscle lysosomes contain glycogen. Int. J. Biochem. \n                           21, 561\u2013567 (1989).","journal-title":"Int. J. Biochem."},{"key":"14063_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1042\/BJ20111416","volume":"441","author":"PJ Roach","year":"2012","unstructured":"Roach, P. J., Depaoli-Roach, A. A., Hurley, T. D. & Tagliabracci, V. S. Glycogen and its metabolism: some new developments and old themes. Biochem. J. \n                           441, 763\u2013787, https:\/\/doi.org\/10.1042\/BJ20111416 (2012).","journal-title":"Biochem. J."},{"key":"14063_CR29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.1207056","volume":"334","author":"R Zoncu","year":"2011","unstructured":"Zoncu, R. et al. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science \n                           334, 678\u2013683, https:\/\/doi.org\/10.1126\/science.1207056 (2011).","journal-title":"Science"},{"key":"14063_CR30","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/emboj.2012.32","volume":"31","author":"C Settembre","year":"2012","unstructured":"Settembre, C. et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. \n                           31, 1095\u20131108, https:\/\/doi.org\/10.1038\/emboj.2012.32 (2012).","journal-title":"EMBO J."},{"key":"14063_CR31","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. \n                           18, 1926\u20131945, https:\/\/doi.org\/10.1101\/gad.1212704 (2004).","journal-title":"Genes Dev."},{"key":"14063_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin, D. A. & Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell \n                           12, 9\u201322, https:\/\/doi.org\/10.1016\/j.ccr.2007.05.008 (2007).","journal-title":"Cancer Cell"},{"key":"14063_CR33","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1126\/science.1187532","volume":"328","author":"RJ Dowling","year":"2010","unstructured":"Dowling, R. J. et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science \n                           328, 1172\u20131176, https:\/\/doi.org\/10.1126\/science.1187532 (2010).","journal-title":"Science"},{"key":"14063_CR34","doi-asserted-by":"publisher","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","volume":"273","author":"N Raben","year":"1998","unstructured":"Raben, N. et al. Targeted Disruption of the Acid -Glucosidase Gene in Mice Causes an Illness with Critical Features of Both Infantile and Adult Human Glycogen Storage Disease Type II. J. Biol. Chem. \n                           273, 19086\u201319092, https:\/\/doi.org\/10.1074\/jbc.273.30.19086 (1998).","journal-title":"J. Biol. Chem."},{"key":"14063_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/hmg\/7.1.53","volume":"7","author":"AGA Bijvoet","year":"1998","unstructured":"Bijvoet, A. G. A. et al. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum. Mol. Genet. \n                           7, 53\u201362, https:\/\/doi.org\/10.1093\/hmg\/7.1.53 (1998).","journal-title":"Hum. Mol. Genet."},{"key":"14063_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ymgme.2008.12.012","volume":"96","author":"S Takikita","year":"2009","unstructured":"Takikita, S., Myerowitz, R., Zaal, K., Raben, N. & Plotz, P. H. Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches. Mol. Genet. Metab. \n                           96, 208\u2013217, https:\/\/doi.org\/10.1016\/j.ymgme.2008.12.012 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"14063_CR37","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/emmm.201202176","volume":"5","author":"C Spampanato","year":"2013","unstructured":"Spampanato, C. et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol. Med. \n                           5, 691\u2013706, https:\/\/doi.org\/10.1002\/emmm.201202176 (2013).","journal-title":"EMBO Mol. Med."},{"key":"14063_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ymgme.2011.05.020","volume":"104","author":"S Kawagoe","year":"2011","unstructured":"Kawagoe, S. et al. Generation of induced pluripotent stem (iPS) cells derived from a murine model of Pompe disease and differentiation of Pompe-iPS cells into skeletal muscle cells. Mol. Genet. Metab. \n                           104, 123\u2013128, https:\/\/doi.org\/10.1016\/j.ymgme.2011.05.020 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"14063_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ajmg.c.31320","volume":"160c","author":"SP Young","year":"2012","unstructured":"Young, S. P. et al. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Am. J. Med. Genet. C Semin. Med. Genet. \n                           160c, 50\u201358, https:\/\/doi.org\/10.1002\/ajmg.c.31320 (2012).","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"14063_CR40","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.stem.2013.04.003","volume":"12","author":"YM Yang","year":"2013","unstructured":"Yang, Y. M. et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell \n                           12, 713\u2013726, https:\/\/doi.org\/10.1016\/j.stem.2013.04.003 (2013).","journal-title":"Cell Stem Cell"},{"key":"14063_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep12831","volume":"5","author":"E Shoji","year":"2015","unstructured":"Shoji, E. et al. Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells. Sci. Rep. \n                           5, 12831, https:\/\/doi.org\/10.1038\/srep12831 (2015).","journal-title":"Sci. Rep."},{"key":"14063_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5966\/sctm.2013-0095","volume":"3","author":"R Abujarour","year":"2014","unstructured":"Abujarour, R. et al. Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery. Stem Cells Transl Med \n                           3, 149\u2013160, https:\/\/doi.org\/10.5966\/sctm.2013-0095 (2014).","journal-title":"Stem Cells Transl Med"},{"key":"14063_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.bbrc.2014.04.084","volume":"448","author":"T Yasuno","year":"2014","unstructured":"Yasuno, T. et al. Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency. Biochem. Biophys. Res. Commun. \n                           448, 175\u2013181, https:\/\/doi.org\/10.1016\/j.bbrc.2014.04.084 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"14063_CR44","doi-asserted-by":"publisher","first-page":"564","DOI":"10.5966\/sctm.2013-0143","volume":"3","author":"T Hosoyama","year":"2014","unstructured":"Hosoyama, T., McGivern, J. V., Van Dyke, J. M., Ebert, A. D. & Suzuki, M. Derivation of myogenic progenitors directly from human pluripotent stem cells using a sphere-based culture. Stem Cells Transl Med \n                           3, 564\u2013574, https:\/\/doi.org\/10.5966\/sctm.2013-0143 (2014).","journal-title":"Stem Cells Transl Med"},{"key":"14063_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051638","volume":"7","author":"T Awaya","year":"2012","unstructured":"Awaya, T. et al. Selective development of myogenic mesenchymal cells from human embryonic and induced pluripotent stem cells. PLoS One \n                           7, e51638, https:\/\/doi.org\/10.1371\/journal.pone.0051638 (2012).","journal-title":"PLoS One"},{"key":"14063_CR46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/jb\/mvi046","volume":"137","author":"K Saito","year":"2005","unstructured":"Saito, K., Araki, Y., Kontani, K., Nishina, H. & Katada, T. Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of rapamycin. J. Biochem. \n                           137, 423\u2013430, https:\/\/doi.org\/10.1093\/jb\/mvi046 (2005).","journal-title":"J. Biochem."},{"key":"14063_CR47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ymgme.2012.09.011","volume":"107","author":"Y Nishiyama","year":"2012","unstructured":"Nishiyama, Y. et al. Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease. Mol. Genet. Metab. \n                           107, 490\u2013495, https:\/\/doi.org\/10.1016\/j.ymgme.2012.09.011 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"14063_CR48","doi-asserted-by":"publisher","first-page":"R1251","DOI":"10.1152\/ajpregu.00212.2014","volume":"307","author":"A Shemesh","year":"2014","unstructured":"Shemesh, A. et al. Suppression of mTORC1 activation in acid-alpha-glucosidase-deficient cells and mice is ameliorated by leucine supplementation. Am. J. Physiol. Regul. Integr. Comp. Physiol. \n                           307, R1251\u20131259, https:\/\/doi.org\/10.1152\/ajpregu.00212.2014 (2014).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"14063_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.15252\/emmm.201606547","volume":"9","author":"JA Lim","year":"2017","unstructured":"Lim, J. A. et al. Modulation of mTOR signaling as a strategy for the treatment of Pompe disease. EMBO Mol. Med. \n                           9, 353\u2013370, https:\/\/doi.org\/10.15252\/emmm.201606547 (2017).","journal-title":"EMBO Mol. Med."},{"key":"14063_CR50","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/onc.2013.113","volume":"33","author":"S Shin","year":"2014","unstructured":"Shin, S. et al. Glycogen synthase kinase-3beta positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene \n                           33, 1690\u20131699, https:\/\/doi.org\/10.1038\/onc.2013.113 (2014).","journal-title":"Oncogene"},{"key":"14063_CR51","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nature06322","volume":"450","author":"JT Cunningham","year":"2007","unstructured":"Cunningham, J. T. et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature \n                           450, 736\u2013740, https:\/\/doi.org\/10.1038\/nature06322 (2007).","journal-title":"Nature"},{"key":"14063_CR52","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/ncb1231","volume":"7","author":"M Ohanna","year":"2005","unstructured":"Ohanna, M. et al. Atrophy of S6K1(\u2212\/\u2212) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. \n                           7, 286\u2013294, https:\/\/doi.org\/10.1038\/ncb1231 (2005).","journal-title":"Nat. Cell Biol."},{"key":"14063_CR53","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.1204592","volume":"332","author":"C Settembre","year":"2011","unstructured":"Settembre, C. et al. TFEB links autophagy to lysosomal biogenesis. Science \n                           332, 1429\u20131433, https:\/\/doi.org\/10.1126\/science.1204592 (2011).","journal-title":"Science"},{"key":"14063_CR54","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.cmet.2008.10.002","volume":"8","author":"CF Bentzinger","year":"2008","unstructured":"Bentzinger, C. F. et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. \n                           8, 411\u2013424, https:\/\/doi.org\/10.1016\/j.cmet.2008.10.002 (2008).","journal-title":"Cell Metab."},{"key":"14063_CR55","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1083\/jcb.200903131","volume":"187","author":"V Risson","year":"2009","unstructured":"Risson, V. et al. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J. Cell Biol. \n                           187, 859\u2013874, https:\/\/doi.org\/10.1083\/jcb.200903131 (2009).","journal-title":"J. Cell Biol."},{"key":"14063_CR56","doi-asserted-by":"publisher","first-page":"20808","DOI":"10.1073\/pnas.1111448109","volume":"108","author":"K Romanino","year":"2011","unstructured":"Romanino, K. et al. Myopathy caused by mammalian target of rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function. Proc. Natl. Acad. Sci. USA \n                           108, 20808\u201320813, https:\/\/doi.org\/10.1073\/pnas.1111448109 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"14063_CR57","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","volume":"17","author":"LD Osellame","year":"2013","unstructured":"Osellame, L. D. et al. Mitochondria and quality control defects in a mouse model of Gaucher disease\u2013links to Parkinson\u2019s disease. Cell Metab. \n                           17, 941\u2013953, https:\/\/doi.org\/10.1016\/j.cmet.2013.04.014 (2013).","journal-title":"Cell Metab."},{"key":"14063_CR58","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/hmg\/ddr610","volume":"21","author":"R de Pablo-Latorre","year":"2012","unstructured":"de Pablo-Latorre, R. et al. Impaired parkin-mediated mitochondrial targeting to autophagosomes differentially contributes to tissue pathology in lysosomal storage diseases. Hum. Mol. Genet. \n                           21, 1770\u20131781, https:\/\/doi.org\/10.1093\/hmg\/ddr610 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"14063_CR59","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","volume":"124","author":"YH Chien","year":"2009","unstructured":"Chien, Y. H. et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics \n                           124, e1116\u20131125, https:\/\/doi.org\/10.1542\/peds.2008-3667 (2009).","journal-title":"Pediatrics"},{"key":"14063_CR60","doi-asserted-by":"publisher","first-page":"16768","DOI":"10.1074\/jbc.M601876200","volume":"281","author":"T Soga","year":"2006","unstructured":"Soga, T. et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. \n                           281, 16768\u201316776, https:\/\/doi.org\/10.1074\/jbc.M601876200 (2006).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14063-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14063-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T12:21:34Z","timestamp":1671798094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14063-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,18]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["14063"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-14063-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,18]]},"assertion":[{"value":"8 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13473"}}